A 4-year follow-up study carried out by Parnetti et al. [33] measured CSF Aβ40, Aβ42, T-tau and P-tau181 in patients with AD, stable MCI (MCI-MCI) and MCI evolving into ADD (MCI-AD) in order to evaluate the power of each biomarker and/or their combination in predicting AD progression. Here, MAPT is linked to Alzheimer disease.